Free Trial
NASDAQ:MAZE

Maze Therapeutics Q2 2025 Earnings Report

Maze Therapeutics logo
$24.88 +1.21 (+5.11%)
As of 09/23/2025 04:00 PM Eastern

Maze Therapeutics EPS Results

Actual EPS
-$0.77
Consensus EPS
-$0.79
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Maze Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$12.50 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Maze Therapeutics Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
4:00PM ET

Maze Therapeutics Earnings Headlines

Maze Therapeutics, Inc. (MAZE): A Bull Case Theory
Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
HC Wainwright Reaffirms Buy Rating for Maze Therapeutics (NASDAQ:MAZE)
Maze Therapeutics, Inc. (MAZE): A Bull Case Theory 
See More Maze Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Maze Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Maze Therapeutics and other key companies, straight to your email.

About Maze Therapeutics

Maze Therapeutics (NASDAQ:MAZE) (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas. By integrating large‐scale genetic datasets with functional genomics assays, the company seeks to uncover previously unrecognized pathways that can be modulated by small molecules or biologics. Its target selection strategy is designed to deliver higher confidence in clinical proof‐of‐concept studies, and Maze’s research collaborations with academic and industry partners support the advancement of its most promising candidates through preclinical and early clinical stages.

Headquartered in South San Francisco, California, Maze Therapeutics operates within a vibrant biotech cluster and draws on a network of scientific advisors and strategic collaborators worldwide. The company is led by a management team with extensive experience in genomics, drug development and translational research. By focusing on genetically validated targets and a disciplined go-to-clinic approach, Maze aims to bring transformative therapies to patients in need while creating value for its shareholders.

View Maze Therapeutics Profile

More Earnings Resources from MarketBeat